Companies
SetPoint Medical
received FDA approval in July 2025 for its neuroimmune modulation therapy for rheumatoid arthritis, the first clinically proven neuromodulation treatment for the condition, and its RESET-RA study was published in Nature Medicine in January 2026 demonstrating durable efficacy and safety;…
- Country
- United States
FDA approved
Neuroimmune modulation
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $432.4 million in total funding as of 2026-09-01 | salestools.io · setpointmedical.com |
| Capacity | tens of thousands of units for several years medium confidence | valley.labusinessjournal.com |
| Regulatory approval | FDA approval received in July 2025 for the SetPoint System to treat rheumatoid arthritis | setpointmedical.com · accessdata.fda.gov · empr.com |
| Production site | United States medium confidence | valley.labusinessjournal.com |
| Headcount | 103 employees as of 2026-09-01 | salestools.io |
Independent sources: accessdata.fda.gov · empr.com · salestools.io · valley.labusinessjournal.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioelectronic medicine & neuromodulation | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.